Table 1 Baseline characteristics of ACC patients treated with chemoradiation by treatment cohort

Treatment center (TBCC/CCI)

18 (100%)/0 (0%)

0 (0%)/17 (100%)

<0.001

Age, y (median(range))

61 (45.1, 85.1)

52 (34.8, 69.7)

0.0045

Gender, (male/female)

6 (33.3%)/12 (66.7%)

4 (23.5%)/13 (76.5%)

0.71

Smoker

4 (22.2%)

11 (64.7%)

0.02

ECOG status

ECOG 0

4 (22.2%)

7 (41.2%)

0.29

ECOG ≥1

14 (77.8%)

10 (58.8%)

Histology

Squamous

17 (94.4%)

17 (100%)

1.00

Other

1 (5.6%)

0 (0%)

AJCC T-stage

1

1 (5.6%)

0 (0%)

1.00

2

8 (44.4%)

7 (41.2%)

3

7 (38.9%)

8 (47.1%)

4

2 (11.1%)

2 (11.8%)

AJCC N-stage

N0

14 (77.8%)

11 (64.7%)

1.00

N1-3

4 (23.2%)

6 (36.3%)

Pretreatment Blood Counts

(median(range))

Hb (g/dL)

124.5 (101, 156)

141 (101, 163)

0.10

WBC (x10⁹/L)

7.8 (5.1, 14.3)

8.6 (5.2, 15.5)

0.70

Neutrophil (x10⁹/L)

5.7 (2.8, 10.3)

6.3 (2.7, 11.3)

0.60

Platelet (x10⁹/L)

287.5 (146, 525)

287 (167, 368)

0.96

RT dose to Primary Tumor, Gy

54 (54, 55.4)

54 (54, 54)

0.04

(median(range))

Chemotherapy

Cisplatin + 5FU

2 (11.1%)

0 (0%)

<0.001

MMC 1 cycle + 5FU

16 (88.9%)

1 (5.9%)

MMC 2 cycles + 5FU

0 (0%)

16 (94.1%)